What impacts the cost-effectiveness of PD-L1 testing in non-small cell lung cancer?

Programmed Death Ligand 1(PD-L1) testing is recommended for patients with Non Small Cell Lung Cancer (NSCLC) at stage IIIB and IV, adenocarcinoma and squamous cell carcinoma. Up to now, no clinical-pathological parameters are perfectly able to select a positive PD-L1-patient. For this reason PD-L1 testing is mandatory for patients with advanced NSCLC for whom an immune checkpoint inhibitor treatment is appropriate. Several studies on the cost-effectiveness of immune checkpoint inhibitors in this subset of patients have been published [1 –3].

Source: Lung Cancer - March 10, 2019 Category: Cancer & Oncology Authors: Sara Bravaccini Source Type: research